Shorts down from 230K to 154K, page-2

Pivalde...I understand and share your frustration with Kemplar, et.al. As you have pointed out, commercializing PBT2 to combat antibiotic resistance is proving to be a long and arduous task along with no real positive news yet regarding the ATH434 Phase 2 Trial. As a result, our SP has plummeted. I feel that because they have purposely kept an extremely low profile with regard to any notable progress by The Fund and Big Pharma and others that are sure to be involved, we have no choice but to "trust the process" and hope and pray it all works out before February 2023. Hang in there and thank you so much for all you do for all of the shareholders.
Barry H.
P.S. I also think we ALL should send an e-mail to The Fund respectfully asking that they PLEASE provide financial support to Alterity to advance the process of any additional development of PBT2 that may be necessary or required. Finally, we should also remind them that the clock is ticking and millions are dying!